Trial ID
EZM0414
Sponsor ID
SET-101
A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
Principal Investigator
Mitul Gandhi, MDLocations
Fairfax Office
Learn More About This Trial
Other Relevant Trials
Trial ID
21552
Sponsor ID
RGX-104-001
“A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (RGX-104-001)”
Principal Investigator
Alexander I. Spira, MD, PhD, FACP
Trial ID
21273
Sponsor ID
GS-US-558-5915
“GS-US-558-5915: A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma”
Principal Investigator
Mitul Gandhi, MD
3 Locations
